Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Cerilliant
Federal Trade Commission
Teva
Dow
Accenture
McKinsey
Boehringer Ingelheim
Chubb

Generated: December 18, 2018

DrugPatentWatch Database Preview

OXYTROL Drug Profile

« Back to Dashboard

When do Oxytrol patents expire, and what generic alternatives are available?

Oxytrol is a drug marketed by Allergan Sales Llc and is included in two NDAs. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-two patent family members in twenty countries.

The generic ingredient in OXYTROL is oxybutynin. There are sixteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the oxybutynin profile page.

Drug patent expirations by year for OXYTROL
Pharmacology for OXYTROL
Synonyms for OXYTROL
(+/-)-oxybutynin
(+/-)-OXYBUTYNIN(Hydrochloride form)
1508-65-2 (hydrochloride)
27815-EP2269989A1
27815-EP2275420A1
27815-EP2280008A2
27815-EP2298767A1
27815-EP2314587A1
4-(Diethylamino)-2-butynyl .alpha.-phenylcyclohexaneglycolate
4-(Diethylamino)-2-butynyl alpha-phenylcyclohexaneglycolic acid ester
4-(Diethylamino)-2-butynyl cyclohexyl(hydroxy)phenylacetate #
4-(diethylamino)-2-butynyl-alpha-cyclohexyl-alpha-hydroxybenzeneacetate
4-(diethylamino)-2-butynyl-alpha-phenylcyclohexaneglycolate
4-(diethylamino)but-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate
4-(diethylamino)but-2-yn-1-yl cyclohexyl(hydroxy)phenylacetate
4-(diethylamino)but-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenyl-acetate
4-(diethylamino)but-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenylacetate
4-Diethylamino-2-butinyl alpha-cyclohexylmandelat
4-Diethylamino-2-butynyl alpha-phenylcyclohexaneglycolate
4-diethylaminobut-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenylacetate
5633-20-5
633O205
AB0013281
AB2000274
AC-2153
AC1L1ILV
AK162584
AKOS015896242
AN-14276
Anturol
Anturol (TN)
API0007236
AX8146542
BDBM50165019
Benzeneacetic acid, alpha-cyclohexyl-alpha-hydroxy-, 4-(diethylamino)-2-butynyl ester
BPBio1_000214
BRD-A65013509-003-03-8
BSPBio_000194
C-20821
C07360
CC-33425
CCG-205005
CCRIS 1923
CHEBI:7856
CHEMBL1231
CS-2255
Cyclohexaneglycolic acid, .alpha.-phenyl-, 4-(diethylamino)-2-butynyl ester
Cyclohexaneglycolic acid, alpha-phenyl-, 4-(diethylamino)-2-butynyl ester
Cystrin
D00465
D0F5LH
DB01062
Ditropan
Ditropan Xl
Ditropan;Lyrinel XL;Oxytrol
DR001867
DTXSID0023406
FT-0082890
FT-0603679
GTPL359
HSDB 3270
HY-B0267
I06-2117
K-9978
kentera
KS-00000GVI
KS-5221
L000923
Lopac0_000923
LP048773
LS-28714
Lyrinel XL
MCULE-3407007074
MFCD00865252
MLS006010052
MolPort-003-849-741
MRF-0000601
NCGC00015767-03
NCGC00015767-04
NCGC00015767-06
NCGC00015767-07
NCGC00015767-09
NCGC00089795-02
O222
OR285581
Oxibutinina
Oxibutinina [INN-Spanish]
Oxibutyninum
Oxybutinin
oxybutynin
Oxybutynin (Ditropan)
Oxybutynin (USAN/INN)
Oxybutynin [USAN:INN:BAN]
Oxybutynin Base
oxybutynin topical gel
Oxybutynin transdermal
Oxybutynin transdermal patch
OXYBUTYNIN, Oxybutynin chloride
Oxybutynine
Oxybutynine [INN-French]
Oxybutyninum
Oxybutyninum [INN-Latin]
Oxytrol (TN)
Pollakisu
Prestwick0_000287
Prestwick1_000287
Prestwick2_000287
Prestwick3_000287
s1754
SBI-0050898.P002
SC-26752
SCHEMBL2992
SMR001550466
SPBio_002413
ST24048863
transdermal patch
XIQVNETUBQGFHX-UHFFFAOYSA-N

US Patents and Regulatory Information for OXYTROL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan Sales Llc OXYTROL oxybutynin FILM, EXTENDED RELEASE;TRANSDERMAL 021351-002 Feb 26, 2003 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Allergan Sales Llc OXYTROL FOR WOMEN oxybutynin FILM, EXTENDED RELEASE;TRANSDERMAL 202211-001 Jan 25, 2013 OTC Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Allergan Sales Llc OXYTROL oxybutynin FILM, EXTENDED RELEASE;TRANSDERMAL 021351-002 Feb 26, 2003 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Allergan Sales Llc OXYTROL FOR WOMEN oxybutynin FILM, EXTENDED RELEASE;TRANSDERMAL 202211-001 Jan 25, 2013 OTC Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for OXYTROL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan Sales Llc OXYTROL oxybutynin FILM, EXTENDED RELEASE;TRANSDERMAL 021351-002 Feb 26, 2003 ➤ Sign Up ➤ Sign Up
Allergan Sales Llc OXYTROL oxybutynin FILM, EXTENDED RELEASE;TRANSDERMAL 021351-002 Feb 26, 2003 ➤ Sign Up ➤ Sign Up
Allergan Sales Llc OXYTROL oxybutynin FILM, EXTENDED RELEASE;TRANSDERMAL 021351-002 Feb 26, 2003 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for OXYTROL
Drugname Dosage Strength RLD Date
➤ Subscribe Transdermal System Extended-re 3.9 mg/24 hrs ➤ Subscribe ➤ Sign Up

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Cerilliant
Federal Trade Commission
Teva
Dow
Accenture
McKinsey
Boehringer Ingelheim
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.